ADCT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ADC Therapeutics SA (ADCT) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available. While technical indicators show some bullish momentum, the company's financial performance is weak, with declining revenue, net income, and EPS. Additionally, there are no significant positive catalysts or strong trading signals to justify immediate investment.
The stock shows bullish momentum with MACD histogram above 0 and positively expanding, RSI at 70.825 in the neutral zone, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at R1: 4.208 and R2: 4.348, while support levels are at S1: 3.753 and S2: 3.613.
Bullish technical indicators and a 70% chance of a 2.46% increase in the next month based on similar candlestick patterns.
Weak financial performance in Q3 2025 with declining revenue (-11.03% YoY), net income (-6.83% YoY), and EPS (-14.29% YoY). No recent news, congress trading data, or significant hedge fund or insider activity.
In Q3 2025, revenue dropped to $16.43M (-11.03% YoY), net income dropped to -$40.97M (-6.83% YoY), EPS dropped to -0.36 (-14.29% YoY), and gross margin dropped to 92.68 (-2.84% YoY).
No recent analyst rating or price target changes available.
